Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258412 | 0.91 | MEN1 (0.53) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL8062394 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL16933991 | 0.90 | LMNA (0.62) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL5834618 | 0.89 | MEN1 (0.55) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL9258093 | 0.89 | MEN1 (0.55) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL8078024 | 0.89 | LMNA (0.58) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL9621406 | 0.89 | LMNA (0.53) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL2415919 | 0.89 | ALDH1A1 (0.54) | LMNASMN1; SMN2MEN1USP2ALDH1A1 | |
| SCHEMBL13303281 | 0.88 | LTA4H (0.57) | CYP3A4LTA4HCYP1A2CYP2D6TSHR | |
| SCHEMBL8076372 | 0.87 | MEN1 (0.60) | LMNASMN1; SMN2MEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671089-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7323585-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7101912-B2 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XENOPORT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005121070-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XIANG JIA-NING (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004052841-A1 | CARBIDOPA PRODRUGS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | PDE3A, ADORA2A, CDA | LMNA 4006/4885SMN1; SMN2 3457/4885MEN1 2470/4885 |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885SMN1; SMN2 229/4885MEN1 1821/4885 |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885SMN1; SMN2 229/4885MEN1 1821/4885 |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | LMNA 2387/4885SMN1; SMN2 229/4885MEN1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.